Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review

Toxicology

Volumn 105, Issue 1, 1995, Pages 23-29

  Sgro, C ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Immunosuppressive agents; Monoclonal antibody; Muromonab CD3; Orthoclone OKT3; Side effects

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; OKT 3;

BLOOD CLOTTING DISORDER; CANCER; CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; IMMUNOSTIMULATION; IMMUNOTOXICITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANIMALS; BINDING, COMPETITIVE; BLOOD COAGULATION DISORDERS; COMMUNICABLE DISEASES; CYTOKINES; GRAFT REJECTION; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

MURINAE;

EID: 0029565168     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-483X(95)03123-W     Document Type: Review

References (45)

1. Release of tumor necrosis factor interleukine-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients
2. Anaphylactic shock after retreatment with OKT3 monoclonal antibody
3. Induction of thromboses within renal grafts by high-dose prophylactic OKT3
4. OKT3 for induction of immunosuppression in renal transplantation
5. Incidence of lymphoproliferative disease in OKT3-treated renal transplant recipients
6. Analysis of infectious complications occuring after solid organ transplantation
7. Acute clinical syndrome associated with OKT3 administration, prevention by single injection of an anti-human TNF monoclonal antibody
8. In vivo cell activation following OKT3 administration
9. Corticosteroid inhibition of the OKT3-induced cytokine-released syndrome, dosage and kinetics prerequisites
10. Treatment of acute renal rejection with OKT3 monoclonal antibody
11. Aseptic meningitis associated with muromonab CD3, DICP
12. Succesfull retreatment of allograft rejection with OKT3
13. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy)
14. Lymphoproliferative syndromes associated with Epstein-Barr virus in transplantation
15. A retrospective analysis of the effect of indomethacin on adverse reactions to Orthoclone OKT3 in the therapy of acute renal allograft rejection
16. Overview of the development of orthoclone OKT3 monoclonal antibody for therapeutic use in transplantation
17. Monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3
18. Main graft vessels thromboses due to conventionnal-dose OKT3 in renal transplantation
19. A 2-year follow-up of posttransplantation malignancy in renal allograft recipients receiving muromonab-CD3 for immunosuppressive induction therapy
20. Orthoclone OKT3 in the treatment of acute renal allograft rejection
21. Prevalence of invasive cytomegalovirus disease with administration of Muromonab CD3 in patients undergoing orthoptic liver transplantation
22. Doppier sonography and renal graft thromboses after OKT3 treatment
23. OKT3 in renal transplantation
24. Prediction of successful allograft rejection retreatment with OKT3
25. Aseptic encephalitis and blindness complicating OKT3 therapy
26. Reexposure to OKT3 in allograft recipients
27. Encephalopathy associated with muromonab CD3
28. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation
29. Incidence of non-Hodgkin's lymphoma in kidney and heart transplant recipients
30. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
31. Cancers complicating organ transplantation
32. OKT3 induction and steroid maintenance immunosuppression for the treatment of high-risk heart transplant recipients
33. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association to distinct mediators
34. Thromboembolic complications and dose of monoclonal OKT3 antibody
35. Complement activation during OKT3 treatment. A possible explanation for respiratory side-effects
36. Cerebrospinal fluid inflammation during OKT3 therapy
37. Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage
38. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving 0KT3 therapy
39. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
40. Muromonab CD3, a review of pharmacology and therapeutic potential
41. Complications and monitoring of OKT3 therapy
42. Les thromboses vasculaires du rein transplante : épidémiologie et facteurs de risque
43. Effect of oral pentoxifilline on the OKT3-induced CRS syndrome
44. Anaphylactic hypersensitivity reaction after repeat OKT3 treatment
45. Oral pentoxifilline as inhibition of CRS syndrome induced by anti-CD3 stimulation